Antipsychotic Drugs Weight Gain and Schizophrenia Case Study

  • Length: 3 pages
  • Sources: 3
  • Subject: Psychiatry
  • Type: Case Study
  • Paper: #19240060

Excerpt from Case Study :

Particularly after her PANSS test results, the client in this case has been diagnosed with schizophrenia, paranoid type, in which positive symptoms like delusions are prevalent. The purpose of this paper is to clarify three key psychopharmacological treatment decisions made on behalf of the client. Goals of all three decisions are symptom reduction and the promotion of the client's mental health and psychosocial functioning.


The decision was to give the patient Invega Sustenna (paliperidone palmitate) 234 mg intramuscular X1 followed by 156 mg intramuscular on day 4 and monthly thereafter, instead of either Zyprexa (olanzapine) or Abilify. The reasoning is based primarily on the fact that Invega Sustenna is a long-acting injectable with fewer compliance complications than orally administered drugs. Although Abilify has been available as a long-acting injectable, Invega Sustenna is recommended in this case because it presents fewer side effects than either Zyprexa or Abilify, particularly those the client has been concerned about such as weight gain (Khanna et al., 2016). Moreover, Invega Sustenna is a second-generation antipsychotic known to be "better tolerated and have fewer adverse neurological side effects" than first-generation drugs (Park, et al., 2013, p. 651).

The client returned to the clinic for follow-up four weeks after the initial injection of Invega Sustenna. The PANSS was re-administered and the client's score decreased by 25%, revealing improvement. The client reports no troublesome side effects from the medication, although she complains of immediate pain at the injection site that lasts for several hours as well as some weight gain. However, neither of these are serious complications. The husband has agreed to take the client for further injections. It is believed that the switch from orally administered antipsychotics will be beneficial for this client, and it is strongly recommended that the client stay with Invega Sustenna given the promising initial results of the PANSS test.

Decision 2

Because the client expressed concern over not being able to sit or walk comfortably after the injection, it was recommended that the administering nurse inject at the deltoid site instead. As pain at the injection site is a concern due to the need to maintain patient compliance with the medication schedule, switching the site should not be a problem.

This decision worked well, as the client directly told the nurses that the pain was much less problematic at the arm site. However, the client has gained more weight -- up again from the first injection to now a total of 4.5 pounds over two months. The client claims that "her husband might not like it,"…

Sources Used in Document:


Amiaz, R., Rubenstein, K., Czerniak, E. et al. (2016). A Diet and Fitness Program Similarly Affects Weight Reduction in Schizophrenia Patients Treated with Typical or Atypical Medications. Pharmacopsychiatry 49(3): 112-116.

Bak, M., et al. (2014). Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis. PLoS ONE 9(4): e94112. doi:10.1371/journal.pone.0094112

Khanna, et al. (2016). Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD006569. DOI: 10.1002/14651858.CD006569.pub5.

Park, E.J. et al. (2013). Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Archives of Pharmacal Research 36(6): 651-659.

Cite This Case Study:

"Antipsychotic Drugs Weight Gain And Schizophrenia" (2017, January 07) Retrieved July 9, 2020, from

"Antipsychotic Drugs Weight Gain And Schizophrenia" 07 January 2017. Web.9 July. 2020. <>

"Antipsychotic Drugs Weight Gain And Schizophrenia", 07 January 2017, Accessed.9 July. 2020,